In a world-first breakthrough, a baby with the rare, deadly CPS1 deficiency received a fully personalized CRISPR base-editing therapy tailored to his unique gene mutation. Created in just six months, the treatment showed remarkable early success, reducing risks and improving development- offering new hope for treating ultra-rare genetic disorders with custom-made therapies.